- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03839381
Turkish Version of Mini-BESTest, Validity and Reliability for Adult Participants With Sensoriomotor Impairments
Turkish Version of Mini-BESTest- Balance Evaluation Systems Test: A Translation and Transcultural Adaptation Study Incorporating Validity and Reliability Analysis for Adult Participants With Sensoriomotor Impairments
Study Overview
Status
Conditions
Detailed Description
Physical therapists encounter postural control problems frequently. These problems require multifaceted assessment. Therefore, the treatment of postural control problems should be planned after a multifaceted assessment.
Balance Evaluation Systems Test (BESTest) comprises 27 items and evaluate all components of postural control. MiniBESTest is a shortened version of BESTest with 14 tasks. MiniBESTest still addresses almost all components of postural control and can be performed 15 min. MiniBESTest is one of the most common methods which practiced on adult patients.
The aim of this study is to present the Turkish version of miniBESTest which evaluates the reasons of balance deficit and postural control. Accordingly, a practice of validity and reliability on adult participants with sensoriomotor impairments will be performed by utilizing the Turkish version of miniBESTest in this study.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Clinical diagnosis of sensoriomotor impairment Able to walk with or without an assistive device (e.g. walker, cane, ankle-foot orthosis...) Ability to tolerate the balance tasks without fatigue.
Exclusion Criteria:
Severe cognitive or communication impairments Hemodynamic or clinical instability.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mini BESTest
Time Frame: 10-15 minutes.
|
Mini-BESTest focuses on dynamic balance.
It includes a total of 14 different tasks, each rated on a 3-level between 0 (severe postural control impairment) and 2 (no postural control impairment) with a maximal score of 28.
|
10-15 minutes.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Franchignoni F, Horak F, Godi M, Nardone A, Giordano A. Using psychometric techniques to improve the Balance Evaluation Systems Test: the mini-BESTest. J Rehabil Med. 2010 Apr;42(4):323-31. doi: 10.2340/16501977-0537.
- Horak FB, Wrisley DM, Frank J. The Balance Evaluation Systems Test (BESTest) to differentiate balance deficits. Phys Ther. 2009 May;89(5):484-98. doi: 10.2522/ptj.20080071. Epub 2009 Mar 27.
- Lemay JF, Roy A, Nadeau S, Gagnon DH. French version of the Mini BESTest: A translation and transcultural adaptation study incorporating a reliability analysis for individuals with sensorimotor impairments undergoing functional rehabilitation. Ann Phys Rehabil Med. 2019 May;62(3):149-154. doi: 10.1016/j.rehab.2018.12.001. Epub 2018 Dec 27.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Wounds and Injuries
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Brain Injuries
- Multiple Sclerosis
- Parkinson Disease
- Brain Injuries, Traumatic
Other Study ID Numbers
- ORDU345
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States